GPT and fibrosis: A viral load of 2000 IU/mL is a strong risk predictor of HCC, an abnormal ALT level, and liver cirrhosis.[30] Some hepatologists suggest NA therapy only if HBV DNA is more than 2000 IU/mL.[31] It has been controversial whether patients need NAs if HBV DNA is less than 2000 IU/mL in non-cirrhotic patients.[22] However, low-level persistent viremia could be associated with liver disease progression, and some patients might transition to the immune-active phase annually.[32] NAs were indicated in patients with advanced fibrosis.